


Piramal announces large scale expansion of API manufacturing facilities

10 October 2017 | News

A part of this investment will go into new state-of-the-art, multi-purpose plants, with over 270kL of total capacity



Piramal Pharma Solutions (PPS) which is a leading Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Enterprises Ltd. (PEL) has announced investments of \$55 million across its sites in North America & Asia, to expand its API manufacturing capabilities and capacities.

A part of this investment will go into new state-of-the-art, multi-purpose plants, with over 270kL of total capacity, to support the current pipeline of approximately 80 late stage programs that PPS is currently assisting its partners with at various global sites.

PPS will also expand its potency footprint at its plant in Riverview, Michigan, while augmenting early development capabilities out of Ennore, India through additions of GMP kilo labs and a pilot plant. It will also add early development capabilities in both, drug substance and drug product, out of its Morpeth, UK facility. Support functions such as Analytical capabilities, R&D infrastructure, automation, and IT systems will also be expanded at all API sites through this investment.

Vivek Sharma, CEO, Piramal Pharma Solutions said, "We are committed towards investing in our customers future needs. With these investments, we can now support the commercialisation of our pipeline of over 80 programs that are at Phase II or beyond, while allowing us additional capacity for future partnerships."

"There has been significant customer interest in our 'integrated' offerings, and we are pleased to have over 60 integrated programs at PPS across all phases of drug development. We thank our customers for their trust and support and promise to continue the focus on the three pillars that made us their Partner of Choice: Customer Centricity, Quality, and Innovation", he also added.